↓ Skip to main content

3-Chloro-N′-(2-hydroxybenzylidene) benzohydrazide: An LSD1-Selective Inhibitor and Iron-Chelating Agent for Anticancer Therapy

Overview of attention for article published in Frontiers in Pharmacology, September 2018
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Good Attention Score compared to outputs of the same age and source (68th percentile)

Mentioned by

twitter
5 X users

Citations

dimensions_citation
13 Dimensions

Readers on

mendeley
23 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
3-Chloro-N′-(2-hydroxybenzylidene) benzohydrazide: An LSD1-Selective Inhibitor and Iron-Chelating Agent for Anticancer Therapy
Published in
Frontiers in Pharmacology, September 2018
DOI 10.3389/fphar.2018.01006
Pubmed ID
Authors

Federica Sarno, Chiara Papulino, Gianluigi Franci, Jeanette H. Andersen, Bastien Cautain, Colombina Melardo, Lucia Altucci, Angela Nebbioso

X Demographics

X Demographics

The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 23 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 3 13%
Student > Master 3 13%
Student > Bachelor 2 9%
Professor 1 4%
Lecturer > Senior Lecturer 1 4%
Other 2 9%
Unknown 11 48%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 5 22%
Chemistry 4 17%
Pharmacology, Toxicology and Pharmaceutical Science 2 9%
Unknown 12 52%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 May 2024.
All research outputs
#15,222,737
of 25,844,183 outputs
Outputs from Frontiers in Pharmacology
#4,807
of 20,024 outputs
Outputs of similar age
#178,950
of 347,232 outputs
Outputs of similar age from Frontiers in Pharmacology
#118
of 397 outputs
Altmetric has tracked 25,844,183 research outputs across all sources so far. This one is in the 40th percentile – i.e., 40% of other outputs scored the same or lower than it.
So far Altmetric has tracked 20,024 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.4. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 347,232 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 47th percentile – i.e., 47% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 397 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 68% of its contemporaries.